304439-23-4

Basic information

• Product Name: (3aS,6aR)-4-(5-broMopentyl)tetrahydro-1H-thieno[3,4-d]iMidazol-2(3H)-one
• Synonyms: (3aS,6aR)-4-(5-broMopentyl)tetrahydro-1H-thieno[3,4-d]iMidazol-2(3H)-one;(3aS,4S,6aR)-4-(5-Bromopentyl)tetrahydro-1H-thieno[3,4-d]imidazol-2(3H)-one;(3AS,6AR)-4S-(5-BROMOPENTYL)TETRAHYDRO-1H-THIENO[3,4-D]IMIDAZOL-2(3H)-ONE
• CAS NO: 304439-23-4
• Molecular Formula: C10H17BrN2OS
• Molecular Weight: 293.22378
• Mol File: 304439-23-4.mol

Chemical Properties

• Boiling Point: 498.3±30.0 °C(Predicted)
• Appearance: /
• Density: 1.387±0.06 g/cm3(Predicted)
• PKA: 13.90±0.40(Predicted)
• CAS DataBase Reference: (3aS,6aR)-4-(5-broMopentyl)tetrahydro-1H-thieno[3,4-d]iMidazol-2(3H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: (3aS,6aR)-4-(5-broMopentyl)tetrahydro-1H-thieno[3,4-d]iMidazol-2(3H)-one(304439-23-4)
• EPA Substance Registry System: (3aS,6aR)-4-(5-broMopentyl)tetrahydro-1H-thieno[3,4-d]iMidazol-2(3H)-one(304439-23-4)

Safety Data

• Hazardous Substances Data: 304439-23-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(3aS,6aR)-4-(5-bromopentyl)tetrahydro-1H-thieno[3,4-d]imidazol-2(3H)-one is used as a potential candidate for the development of novel drugs due to its unique molecular structure and possible pharmacological properties. It may be utilized in the treatment of certain diseases or conditions, pending further research and evaluation of its characteristics, interactions, and effects.

Upstream product

• 608-16-2 biotin methyl ester 
• 58-85-5 biotin 
• 53906-36-8 1H-thieno<3,4-d>imidazol-2(3H)-one, tetrahydro-4-(5-hydroxypentyl)-, <3aS-(3aα,4β,6aα)>- 
• 87573-52-2 5-[(3aS,4S,6aR)-2-oxo-hexahydro-thieno[3,4-d]imidazol-4-yl]-pentanoic acid ethyl ester 
• 69705-14-2 5-((3a5,45,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentyl 4-methylbenzenesulfonate 

Relevant articles and documents

Molecular recognition studies on naphthyridine derivatives

The association constants Kb of three hosts I-III designed to have both enhanced hydrogen bonding donor strength and conformational preorganization with biotin analogues 1-5 are reported. 1H-NMR titrations under two different concent

Synthesis of a biotin-derived alkyne for Pd-catalyzed coupling reactions

An efficient synthesis of a terminal alkyne derived from d-biotin was developed to provide an alternative for carboxyi-based biotinylation. This approach was illustrated by the preparation of alkyne- and alkene-linked phenylalanine derivatives using palladium-catalyzed Sonogashira and Oh methodology. (Strept)avidin binding was observed using soluble and immobilized receptors. These results demonstrate the applicability of carbon-linked biotin derivatives for use in affinity-based purification and bioanalytical applications.

Triazole biotin: A tight-binding biotinidase-resistant conjugate

The natural amide bond found in all biotinylated proteins has been replaced with a triazole through CuAAC reaction of an alkynyl biotin derivative. The resultant triazole-linked adducts are shown to be highly resistant to the ubiquitous hydrolytic enzyme biotinidase and to bind avidin with dissociation constants in the low pM range. Application of this strategy to the production of a series of biotinidase-resistant biotin-Gd-DOTA contrast agents is demonstrated. The Royal Society of Chemistry 2013.

BIOTINIDASE RESISTANT BIOTINYL COMPOUNDS

Disclosed are biotinidase resistant biotinyl-conjugates, and uses thereof. The conjugates comprise a biotinyl moiety coupled to a therapeutic or diagnostic moiety by a triazole group. The conjugates have applications as diagnostic or therapeutic agents, in methods of diagnosis or treatment of a subject, for example as MRI contrast agents in MRI imaging of a subject. In particular, biotinyl-chelate complexes find utility in two and three step pretargeting strategies and have high affinity for avidin, streptavidin and related proteins. Also disclosed are biotinylating agents and kits, and the use of compounds for biotinylation, including for the synthesis of biotinyl-chelate complexes and biotinyl-conjugates.

Biotin analogues with antibacterial activity are potent inhibitors of biotin protein ligase

There is a desperate need to develop new antibiotic agents to combat the rise of drug-resistant bacteria, such as clinically important Staphylococcus aureus. The essential multifunctional enzyme, biotin protein ligase (BPL), is one potential drug target f